The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and Wells Fargo are acting as joint book running managers for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics announces $250M common stock offering
- Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes
- Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.
- Mineralys Therapeutics Reports Positive Phase 3 Trial Results
- Mineralys Therapeutics announces results from Launch-HTN, Advance-HTN trials